Abstracts Archive - Page 672 of 2607 - ACR Meeting Abstracts

Abstract Number: 2260 • ACR Convergence 2022
Transcutaneous Vagal Nerve Stimulation Improves Destabilized Medial Meniscus-Induced Osteoarthritis Pain Associated with Significant Serum Biomarker Changes
Shivmurat Yadav¹, Monika Niewiadomska¹, Lynsie Morris², Taylor Conner², Jessica Lumry², Sanique South³, Emmaline Prinz², Matlock Jeffries², Timothy Griffin², Stavros Stavrakis¹ and Mary Beth Humphrey¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ³Oklahoma Medical Research Foundation, Okahoma City, OK
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, affecting over 32.5 million US adults and characterized by pain, stiffness, swelling and functional disability.…
Abstract Number: 2259 • ACR Convergence 2022
Complete Resolution of Inflammation on MRI Is Associated with a Better Clinical Response over Time in Patients with Early Axial Spondyloarthritis
valeria Rios-Rodriguez¹, Murat Torgutalp², Christian Althoff³, Hildrun Haibel², Kay-Geert Hermann², Fabian Proft⁴, Mikhail Protopopov⁵, Judith Rademacher⁵, Joachim Sieper² and Denis Poddubnyy⁴, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Helios Klinikum Emil von Behring, Berlin, Germany, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Magnetic resonance imaging (MRI) of the spine and sacroiliac joints (SIJ) are important tools for the diagnosis of axial SpA and the presence of…
Abstract Number: 2264 • ACR Convergence 2022
Dysregulated Interferon Gamma Signals Promote Systemic Autoimmunity in STAT1 Gain of Function Syndrome
Andrea Largent¹, Jane Buckner², David Rawlings¹ and Shaun Jackson¹, ¹Seattle Children's Research Institute, Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: Heterozygous gain-of-function mutations in STAT1 promote a complex disorder of immune dysregulation including chronic mucocutaneous candidiasis (CMC) and systemic autoimmunity. However, given widespread expression…
Abstract Number: 2267 • ACR Convergence 2022
Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 Interferons in Cutaneous Lupus
Thomas Vazquez¹, Nilesh Kodali¹, DeAnna Diaz², Jay Patel³, Emily Keyes², Grant Sprow², Meena Sharma¹, Mariko Ogawa-Momohara², Madison Grinnell², Josh Dan² and Victoria Werth², ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN
Background/Purpose: Type 1 interferons (IFN-1) are major drivers of disease activity in systemic (SLE) and cutaneous lupus erythematosus (CLE). Plasmacytoid dendritic cells (pDCs) are the…
Abstract Number: 2266 • ACR Convergence 2022
Platelet-selectin Prime Lupus Neutrophils to Produce Mitochondrial ROS and Participate in SLE Pathogenesis
Marc Scherlinger¹, Pierre Vacher², Vivien Guillotin³, Isabelle Douchet⁴, Christophe Richez⁵ and Patrick Blanco⁴, ¹BIDMC Harvard University, Boston, MA, ²INSERM U1218, Bordeaux, France, ³CHU de Bordeaux, Bordeaux, France, ⁴UMR-CNRS 5164 Immunoconcept, Bordeaux, France, ⁵CHRU Bordeaux, Bordeaux, France
Background/Purpose: In patients with active systemic lupus erythematosus (SLE), circulating platelets have an activated phenotype characterized by the expression of P-selectin (CD62P). We have shown…
Abstract Number: 2263 • ACR Convergence 2022
Nanotherapeutic Approaches for the Treatment of Post-traumatic Osteoarthritis
Luke Springer¹, Kelsey Collins², Huimin Yan², Ying Hu³, Farshid Guilak², Samuel Wickline⁴, Hua Pan² and Christine Pham², ¹Washington University School of Medicine, St. Louis, MO, ²Washington University School of Medicine, Saint Louis, MO, ³Washington University, Saint Louis, MO, ⁴University of South Florida, Tampa, FL
Background/Purpose: Osteoarthritis (OA) represents the most common form of arthritis and is a major cause of morbidity in the aging population. Post-traumatic OA (PTOA) is…
Abstract Number: 2245 • ACR Convergence 2022
Feasibility and Efficacy of a Peer Education Program to Improve Patient Engagement in Lupus Clinical Trials
Saira Sheikh¹, Caroline Donovan², Carla Menezes², Albert T. Roy², Andrew Simkus³, Diane Gross⁴, Anca Askanase⁵, Rosalind Ramsey-Goldman⁶, Vikas Majithia⁷, Nicole Wanty³, Annie McNeill³, Kristen Holtz³ and S. Sam Lim⁸, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Lupus Therapeutics, LLC, New York, NY, ³KDH Research & Communication, Atlanta, GA, ⁴Lupus Research Alliance, New York, NY, ⁵Columbia University Medical Center, New York, NY, ⁶Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, ⁷University of Mississippi Medical Center, Ridgeland, MS, ⁸Emory University, Atlanta, GA
Background/Purpose: To assess outcomes related to Lupus Therapeutics' Patient Advocates for Lupus Studies (LT-PALS) a peer-to-peer clinical trial (CT) education program designed to improve CT…
Abstract Number: 2224 • ACR Convergence 2022
Genes Causative of Primary Immunodeficiency Are Risk Factors for and Over-expressed in Systemic Lupus Erythematosus
Haley Davis¹, Adam Labonte¹, Katherine Owen², Erika Hubbard¹, Jessica Kain¹, Brian Kegerreis¹, Prathyusha Bachali³, Amrie Grammer⁴ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²RILITE, Crozet, VA, ³AMPEL BioSolutions, Redmond, WA, ⁴AMPEL LLC, Charlottesville, VA
Background/Purpose: Systemic lupus erythematosus (SLE) is a polygenic autoimmune disease whose specific causes are incompletely understood and for which there exists no single comprehensive diagnostic…
Abstract Number: 2270 • ACR Convergence 2022
Evidence for Mitochondrial Dysfunction in Blood-derived Endothelial Colony Forming Cells Isolated from Patients with Antiphospholipid Syndrome
Lida Kabir, Robert Maughan, Koralia Paschalaki, Anna Randi, David Carling, Deepa Arachchillage, Justin Mason and Charis Pericleous, Imperial College London, London, United Kingdom
Background/Purpose: The endothelium is a major target of pathogenic antiphospholipid antibodies (aPL) found in patients with antiphospholipid syndrome (APS). It is well established that aPL…
Abstract Number: 2274 • ACR Convergence 2022
Factors Associated with Disease Flare Following SARS-CoV-2 Vaccination in People with Inflammatory Rheumatic and Musculoskeletal Diseases – Results from the Physician-Reported EULAR Coronavirus Vaccine (COVAX) Registry
Bayram Farisoğulları¹, Saskia Lawson-Tovey², Kimme Hyrich³, Laure Gossec⁴, Loreto Carmona⁵, Anja Strangfeld⁶, Elsa Mateus⁷, Martin Schaefer⁸, Ana Maria Rodrigues⁹, Eric Hachulla¹⁰, Jose A Gomez-Puerta¹¹, Marta Mosca¹², Patrick Durez¹³, Ludovic Trefond¹⁴, Tiphaine Goulenok¹⁵, Martina Cornalba¹⁶, Emoke Šteňová¹⁷, Inita Bulina¹⁸, Eva Strakova¹⁹, Julija Zepa²⁰, Nicolas Roux²¹, Olivier Brocq²², Viellard Eric²³, Bernd Raffeiner²⁴, Gerd Burmester²⁵, Xavier Mariette²⁶ and Pedro Machado²⁷, ¹Hacettepe University Faculty of Medicine Division of Rheumatology, Ankara, Turkey, ²Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, the University of Manchester, Manchester, UK AND National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³The University of Manchester, Manchester, United Kingdom, ⁴Sorbonne Université, Paris, France, ⁵Instituto de Salud Musculoesquelética (InMusc), Madrid, Spain, ⁶Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ⁷EULAR, Lisboa, Portugal, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, ¹⁰University of Lille, LILLE, France, ¹¹Hospital Clínic de Barcelona, Barcelona, Spain, ¹²Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹³Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ¹⁴Université Clermont Auvergne, CHU Clermont-Ferrand, Service de Médecine Interne, Hôpital Gabriel Montpied, INSERM U1071, Clermont-Ferrand, France, ¹⁵APHP, Paris, France, ¹⁶Dipartimento di Reumatologia e Scienze Mediche, ASST Gaetano Pini-CTO, Milano, Italy, ¹⁷University Hospital, Bratislava, Slovakia, ¹⁸Center of Rheumatology, Paul Stradins Clinical University hospital, Riga, Latvia, Riga, Latvia, ¹⁹Department of Internal Medicine, Faculty Hospital Prešov, Presov, Slovakia, ²⁰Riga Stradins University, Latvia, Pauls Stradins Clinical University Hospital, Centre of Rheumatology, Riga, Latvia, Riga, Latvia, ²¹Service de Rhumatologie, Hôpital Robert Schuman, Metz, France, ²²Rheumatology- CH Princesse Grace, Monaco, Monaco, ²³Private practice, St. Malo, France, ²⁴Department of Rheumatology, Central Hospital of Bolzano, Bolzano, Italy, ²⁵Charité University Medicine Berlin, Berlin, Germany, ²⁶Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ²⁷University College London, London, United Kingdom
Background/Purpose: To investigate the frequency and factors associated with disease flare following vaccination against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMD).Methods: The…
Abstract Number: 2271 • ACR Convergence 2022
Circulating Calprotectin: A Potential New Biomarker for “Non-Criteria” Clinical Manifestations of Antiphospholipid Syndrome
Claire Hoy¹, Naveen Kumar S K¹, Sherwin Navaz¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Noah Peters¹, Tristin Smith¹, Gary Norman³, Gabriel Figueroa Parra⁴, Johann Gudjonsson¹, J. Michelle Kahlenberg¹, Jacqueline Madison¹, Ali Duarte-Garcia⁴, Jason S Knight⁵ and Yu (Ray) Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³INOVA Diagnostics, San Diego, CA, ⁴Mayo Clinic, Rochester, MN, ⁵University of Michigan, Division of Rheumatology, Ann Arbor, MI

Background/Purpose: While thrombosis and pregnancy loss are the best-known features of APS, many patients also exhibit "non-criteria" manifestations such as thrombocytopenia and heart valve damage.…
Abstract Number: 2275 • ACR Convergence 2022
Three Dose SARS-CoV-2 Vaccination Is Associated with Reduced Risk of Breakthrough COVID-19 During Omicron Wave in Patients with Autoimmune Diseases
Caoilfhionn Connolly¹, Rachel Wallwork¹, Teresa Po-Yu Chiang¹, Mayan Teles¹, Jennifer Alejo¹, Allan Massie², Ami Shah³, Jemima Albayda¹, Lisa Christopher-Stine¹, Dorry Segev², William Werbel¹ and Julie Paik¹, ¹Johns Hopkins University, Baltimore, MD, ²NYU Langone Health, New York, NY, ³Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: While SARS-CoV-2 vaccination mitigates the risk of severe COVID-19, vaccinated patients with autoimmune diseases are more susceptible to infection despite vaccination ("breakthrough" COVID-19) and…
Abstract Number: PP02 • ACR Convergence 2022
Patient Mobilization for Vaccine Access and Improved Care During the COVID Pandemic
Marie-Claude Beaulieu¹, Ines Colmegna², Nathalie Amiable³, Jean Légaré⁴ and Paul Fortin⁵, ¹Universite de Sherbrooke, Sherbrooke, QC, Canada, ²The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³CHU de Québec, Quebec, QC, Canada, ⁴QC, Canada, ⁵CHU de Quebec - Universite Laval, Quebec, QC, Canada
Background/Purpose: The COVID pandemic was particularly difficult for persons like me living with rheumatoid arthritis and immunosuppressed. I had to impose myself months of isolation…
Abstract Number: PP01 • ACR Convergence 2022
Why Communication Is the Most Important Thing in Healthcare
India Murphy-Miller, Ardeer, Victoria, Australia
Background/Purpose: My name is India I got diagnosed with JIA when I was 8 and I'm now about to turn 28 so as you can…
Abstract Number: PP06 • ACR Convergence 2022
Search for a New Rheumatologist; What Happened When My Trusted Rheumatologist Retired
Lawrence Phillips, Noblesville, IN
Background/Purpose: I was diagnosed with rheumatoid arthritis (RA) in 1999. In 2015 and 2019, two surgeons independently diagnosed me with ankylosing spondylitis (AS) following two…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].